10,000 Patients Tested With Personalized mRNA Cancer Immunotherapies by 2030

As of January 10, 2022, over 13 billion COVID-19 vaccine doses have been administered — including hundreds of millions of mRNA vaccines by companies like Pfizer/BioNTech and Moderna. Following the surge in mRNA vaccine research for COVID-19, researchers are now seeking to apply their experience to cancer vaccines. Recently, BioNTech announced a strategic partnership with the government of the United Kingdom to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030.

“Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years,” says Prof. Ugur Sahin, CEO and cofounder of BioNTech, in a press release.

“The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide. If successful, this collaboration has the potential to improve outcomes for patients and provide early access to our suite of cancer immunotherapies as well as to innovative vaccines against infectious diseases – in the U.K. and worldwide,” he adds.

You must be logged in to view this content.